CDXS
Codexis, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.45
+1.76%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−8.1x
Market Cap
$158.24M
MomentumView details →
1D Return
+1.76%
YTD Return
−11.35%
RSI (14)
38.4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−8.1x
Market Cap
$158.24M
RSI (14)
38.4
MomentumView details →
1D Return
+1.76%
YTD Return
−11.35%
SummaryUpdated Jun 1, 2026
Codexis, Inc. (NASDAQ:CDXS) is a biotechnology company founded in 2002 and headquartered in Redwood City, California. The company went public in 2010 and specializes in developing engineered enzymes and proteins through its proprietary CodeEvolver protein engineering platform. Codexis has evolved from a broad enzyme development company to focus primarily on pharmaceutical manufacturing applications, particularly in the emerging field of small interfering RNA (siRNA) therapeutics production through its ECO Synthesis platform.
Similar companies
Latest newsMore news →
Codexis reported financial results for the second quarter ended June 30, 2026, with revenue of $14.9 million.24d agoCodexis completed an equity capital raise with approximately $25 million in net proceeds.24d agoCodexis announced a proposed underwritten public offering of shares of its common stock.43d ago